TOP HEADLINES

Featured Story

  • Health agencies inform on Zika vaccine timeline

    Multiple public health authorities have given insight to the timing of Zika vaccine development, with the WHO now stating that any vaccine may be too late for the current outbreak, a similar situation to the one the world experienced in the Ebola epidemic.

NIH-developed dengue vaccine protects all patients in challenge study

As Sanofi works to gain traction for the launch of its world-first dengue vaccine, a potential competitor may be building its case. This week, the National Institutes of Health announced that a candidate developed by scientists there posted "very encouraging" results, according to the team's lead scientist.

Valneva scores $42M supply contract with DOD

Valneva currently markets Ixiaro, a Japanese encephalitis vaccine and Dukoral, the cholera vaccine it acquired from Johnson & Johnson in 2015. Now, the Lyon, France-based vaccine maker is building on its relationship with the U.S. Department of Defense with a new $42 million supply contract for Ixiaro.

Health agencies inform on Zika vaccine timeline

Multiple public health authorities have given insight to the timing of Zika vaccine development, with the WHO now stating that any vaccine may be too late for the current outbreak, a similar situation to the one the world experienced in the Ebola epidemic.

Analyst: Mitsubishi Tanabe's tobacco-based flu jab could have 'significant impact' on market

Following Mitsubishi Tanabe's announcement that its tobacco-based flu vaccine could hit the market by 2018 or 2019, a GlobalData analyst has lauded the Japanese company's candidate as poised to "take over" the flu vaccine market from traditional egg-based vaccines.

Journal walks back 'seriously flawed' study critical of Merck's Gardasil

Citing "seriously flawed" methodology and "unjustified" claims, the journal Vaccine has permanently withdrawn a previously published study critical of Merck's Gardasil.

MORE NEWS

From Our Sister Sites

FierceMarkets Network
  • FierceBiotech
  • FierceBiotechIT
  • FierceBiotechResearch
  • FierceDrugDelivery
  • FierceMedicalDevices
  • FierceVaccines
  • FiercePharma
  • FiercePharmaAsia
  • FiercePharmaManufacturing
  • FierceCRO
  • FierceDiagnostics
  • FiercePharmaMarketing
  • FierceAnimalHealth
  • More Fierce Network sites
FierceMedicalDevices
Aerin Medical raises $16.7M to back radiofrequency device to remodel nasal tissue

There aren't a lot of attractive options to treat nasal breathing disorders. Most are limited to unwieldy devices to aid breathing or surgical alteration of the nasal anatomy. Startup Aerin Medical hopes to offer a novel non-invasive approach--the use of non-ablative radiofrequency energy to target and remodel nasal tissues to treat breathing orders caused by anatomical obstruction and mucosal dysfunction.  

FiercePharma
Amgen's PCSK9 patent win 'reasonably likely' to push Sanofi's Praluent off the market: Analyst

The analyst who warned that Sanofi and Regeneron could owe Amgen hefty royalties on its PCSK9 drug Praluent has come back with a prediction more dire: Chardan's Gbola Amusa says it's "reasonably likely" that the potential blockbuster would be removed from the market completely.